Every Form 4 that Silo Pharma, Inc. (SILO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock. On December 15, 2025, he bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share. After these transactions, he directly beneficially owned 216,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) CEO and director Eric Weisblum reported open-market purchases of company stock. On 11/20/2025, he bought 1,000 shares of common stock at $0.37 per share. On 11/21/2025, he purchased another 1,000 shares at $0.365 per share. Following these transactions, Weisblum beneficially owns 211,932 shares of Silo Pharma common stock, held directly.
Silo Pharma, Inc. insider share purchases reported
A reporting person serving as both a director and Chief Executive Officer of Silo Pharma, Inc. (SILO) filed a Form 4 disclosing open‑market purchases of the company’s common stock. On November 18, 2025, the insider purchased 7,500 shares at a weighted average price of $0.4033 per share. On November 19, 2025, the insider purchased an additional 4,500 shares at a weighted average price of $0.405 per share. Following these transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.